Skip to search formSkip to main contentSkip to account menu

brentuximab vedotin 50 MG Injection [Adcetris]

Known as: Adcetris 50 MG Injection, Brentuximab Vedotin 50 mg in 10.5 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [ADCETRIS] 
National Institutes of Health

Related topics

Related topics

8 relations
AdcetrisInjectionPolysorbate 80TREHALOSE DIHYDRATE

Broader (1)

brentuximab vedotin Injection [Adcetris]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Brentuximab vedotin (Adcetris®) in combination with chemotherapy for CD30-positive peripheral T-cell lymphoma (PTCLs)
Several peripheral T-cell lymphomas (PTCL) express the tumour necrosis factor (TNF) receptor CD30, conferring cell survival and… 
2017
2017
Enzyme-Based Strategies to Generate Site-Specifically Conjugated Antibody Drug Conjugates
Antibody Drug Conjugates (ADCs) exploit the specificity of monoclonal antibodies for the targeting of highly potent small… 
Review
2016
Review
2016
Recent Advances in Site Specific Conjugations of Antibody Drug Conjugates (ADCs).
Antibody-drug conjugates (ADCs) take the advantage of antigen specificity of monoclonal antibodies to deliver highly potent… 
2015
2015
Abstract 3601: Antibody-drug conjugates (ADCs) with tubulysin and PBD warheads, maintain potent in vitro cytotoxicity against multidrug-resistant tumor cells expressing P-glycoprotein (P-gp)
Development of resistance to initially-effective therapies remains a major challenge in the treatment of cancer. Resistance to… 
2014
2014
Brentuximab Vedotin (Adcetris®) for the Treatment of CD30‐Positive Hematologic Malignancies
2014
2014
Abstract 2514: Towards homogenous adcs: A new site-specific antibody conjugation using bacterial transglutaminase (btg-adc)
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Purpose : Bacterial Transglutaminase (BTG) allows coupling… 
2013
2013
Monoclonal Antibody Therapy of T-Cell Leukemia and Lymphoma
T-cell leukemias and lymphomas are a heterogeneous group of uncommon tumors that account for 7-15% of lymphomas. [1] They… 
2013
2013
Studies on the Metabolism of Antibody–Drug Conjugates
Antibody–drug conjugates (ADCs) are targeted anticancer agents that utilize the specificity of monoclonal antibodies (Ab) to… 
2013
2013
Rezidivierte Lymphome zielgerichtet mit Brentuximab Vedotin behandeln
Mit dem Antikörper-Wirkstoff-Konjugat Brentuximab Vedotin (Adcetris®) von Takeda steht seit zwanzig Jahren erstmals wieder eine… 
Review
2012
Review
2012
Brentuximab (Adcetris®) for the treatment of relapsed Hodgkin's lymphoma (HL) or relapsed systemic anaplastic large cell lymphoma (sALCL)
Brentuximab vedotin is an antibody-drug conjugate (ADC) directed against the tumour necrosis factor (TNF) receptor CD30 which is… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)